Literature DB >> 1717142

Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.

G Shaulsky1, N Goldfinger, V Rotter.   

Abstract

To study the mechanism of p53 involvement in malignant transformation, we compared the tumor development patterns induced by a parental p53 nonproducer pre-B cell line with those by cell lines generated from this parental cell line following transfection of either wild type or mutant p53. It was found that whereas mutant p53 facilitated tumor development, expression of wild type p53 restrained tumor development. Cell lines expressing the wild type p53 induced the development of faster regressing tumors than the parental cell line. The parental p53 nonproducer and the wild type p53 producer regressor tumors underwent in vivo cell differentiation, manifested as IgG production. Mutant p53, producer cell lines, on the other hand, failed to show any immunoglobulin synthesis and gave rise to highly proliferative lethal tumors. Our results support the conclusion that these pre-B cells develop regressor tumors because they have undergone differentiation. Whereas the wild type p53 facilitates this differentiation, mutant p53 cells block it. We suggest that, in addition to inactivating the growth-suppressive activity of wild type p53, the expression of mutant p53 facilitates malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717142

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

3.  Not all p53 gain-of-function mutants are created equal.

Authors:  S S Mello; L D Attardi
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

4.  Immunohistochemical studies of sensory neurons in rat olfactory epithelium.

Authors:  C C Huang; K Chen; T Y Huang
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

5.  Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

Authors:  K Will; G Warnecke; L Wiesmüller; W Deppert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

6.  Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Authors:  Yoichi Ohiro; Anny Usheva; Shinichiro Kobayashi; Shannon L Duffy; Regan Nantz; David Gius; Nobuo Horikoshi
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Authors:  Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

8.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck.

Authors:  Yoon Ho Ko; Sang-Young Roh; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Myung Ah Lee; Jin Hyoung Kang; Young Seon Hong; Min Sik Kim; Chan-Kwon Jung
Journal:  Head Neck Oncol       Date:  2010-10-30

10.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Authors:  Rachel Sarig; Noa Rivlin; Ran Brosh; Chamutal Bornstein; Iris Kamer; Osnat Ezra; Alina Molchadsky; Naomi Goldfinger; Ori Brenner; Varda Rotter
Journal:  J Exp Med       Date:  2010-08-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.